By combining irinotecan‐loaded silicasomes with spleen‐targeting LNPs carrying KRAS mRNA, our aim is to enhance the activation of the cancer immunity cycle and overcome the formidable immunosuppressive barriers of PDAC. This evidence concerns the gene KRAS and cancer.